Hao Xu1, Zhuo Chen1, Qing-Hua Shang1, Zhu-Ye Gao1, Chang-An Yu2, Da-Zhuo Shi1, Ke-Ji Chen3. 1. Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. 2. Department of Cardiology, China-Japan Friendship Hospital, Beijing, 100029, China. 3. Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. kjchenvip@163.com.
Abstract
OBJECTIVE: To examine the prognostic value of serum levels of asymmetric dimethylarginine (ADMA) in patients with stable coronary heart disease (CHD) thus explore a potential biomarker of "toxin syndrome" in CHD. METHODS: In this prospective nested case-control study, 36 of 1,503 Chinese patients with stable CHD experienced at least 1 recurrent cardiovascular event (RCE) during 1-year follow-up. Serum levels of ADMA at the start of follow-up were compared between these 36 cases and 36 controls which matched to cases in terms of gender, age, history of hypertension, and myocardial infarction. RESULTS: Based on the crude model, subjects in the 2 highest ADMA quartiles showed significantly higher risk of developing RCE than those in the lowest ADMA quartile [odds ratio (OR) 4.09, 95% confidence interval (CI) 1.01 to 16.58; OR 6.76, 95% CI 1.57 to 29.07]. This association was also observed in the case-mix model (OR 5.51, 95% CI 1.23 to 24.61; OR 7.83, 95% CI 1.68 to 36.41) and multivariable model (OR 6.64, 95% CI 1.40 to 31.49: OR 13.14, 95% CI 2.28 to 75.71) after adjusting for confounders. The multivariable model which combined ADMA and high-sensitivity C-reactive protein (hsCRP) showed better predictive power with areas under the receiver operator characteristic curves (0.779) than the model of either ADMA (0.694) or hsCRP (0.636). CONCLUSION: Serum ADMA level may be a potential biomarker of "toxin syndrome" in CHD which shows favorable prognostic value in predicting 1-year RCE in patients with stable CHD. [The registration number is ChiCTR-PRNRC-07000012].
OBJECTIVE: To examine the prognostic value of serum levels of asymmetric dimethylarginine (ADMA) in patients with stable coronary heart disease (CHD) thus explore a potential biomarker of "toxin syndrome" in CHD. METHODS: In this prospective nested case-control study, 36 of 1,503 Chinese patients with stable CHD experienced at least 1 recurrent cardiovascular event (RCE) during 1-year follow-up. Serum levels of ADMA at the start of follow-up were compared between these 36 cases and 36 controls which matched to cases in terms of gender, age, history of hypertension, and myocardial infarction. RESULTS: Based on the crude model, subjects in the 2 highest ADMA quartiles showed significantly higher risk of developing RCE than those in the lowest ADMA quartile [odds ratio (OR) 4.09, 95% confidence interval (CI) 1.01 to 16.58; OR 6.76, 95% CI 1.57 to 29.07]. This association was also observed in the case-mix model (OR 5.51, 95% CI 1.23 to 24.61; OR 7.83, 95% CI 1.68 to 36.41) and multivariable model (OR 6.64, 95% CI 1.40 to 31.49: OR 13.14, 95% CI 2.28 to 75.71) after adjusting for confounders. The multivariable model which combined ADMA and high-sensitivity C-reactive protein (hsCRP) showed better predictive power with areas under the receiver operator characteristic curves (0.779) than the model of either ADMA (0.694) or hsCRP (0.636). CONCLUSION: Serum ADMA level may be a potential biomarker of "toxin syndrome" in CHD which shows favorable prognostic value in predicting 1-year RCE in patients with stable CHD. [The registration number is ChiCTR-PRNRC-07000012].
Authors: Renate Schnabel; Stefan Blankenberg; Edith Lubos; Karl J Lackner; Hans J Rupprecht; Christine Espinola-Klein; Nicole Jachmann; Felix Post; Dirk Peetz; Christoph Bickel; François Cambien; Laurence Tiret; Thomas Münzel Journal: Circ Res Date: 2005-08-11 Impact factor: 17.367
Authors: Friedrich Mittermayer; Katarzyna Krzyzanowska; Markus Exner; Wolfgang Mlekusch; Jasmin Amighi; Schila Sabeti; Erich Minar; Markus Müller; Michael Wolzt; Martin Schillinger Journal: Arterioscler Thromb Vasc Biol Date: 2006-08-24 Impact factor: 8.311
Authors: Friedrich Schulze; Henrike Lenzen; Christoph Hanefeld; Asja Bartling; Karl J Osterziel; Lilia Goudeva; Caroline Schmidt-Lucke; Magda Kusus; Renke Maas; Edzard Schwedhelm; Dietrich Strödter; Bernd C Simon; Andreas Mügge; Werner G Daniel; Harald Tillmanns; Bernhard Maisch; Thomas Streichert; Rainer H Böger Journal: Am Heart J Date: 2006-09 Impact factor: 4.749
Authors: Jan T Kielstein; Frank Donnerstag; Sandra Gasper; Jan Menne; Anousheh Kielstein; Jens Martens-Lobenhoffer; Fortunato Scalera; John P Cooke; Danilo Fliser; Stefanie M Bode-Böger Journal: Stroke Date: 2006-06-29 Impact factor: 7.914
Authors: Andreas Meinitzer; Ursula Seelhorst; Britta Wellnitz; Gabriele Halwachs-Baumann; Bernhard O Boehm; Bernhard R Winkelmann; Winfried März Journal: Clin Chem Date: 2006-12-21 Impact factor: 8.327